Spots Global Cancer Trial Database for Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer
Official Title: Accurate Prediction and Validation of Response to Neoadjuvant Chemotherapy in Cervical Cancer
Study ID: NCT03229187
Interventions
Study Description
Brief Summary: Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies. However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments. This study is undertaken to build specific molecular signatures to predict the effects of neoadjuvant chemotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Tongji Hospital, Wuhan, Hubei, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
